secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001193125-24-045328
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics appoints Marella Thorell as CFO; David Arkowitz retires March 15
--------------------------------------------------------------------------------

- Marella Thorell named EVP and CFO effective March 25, 2024; David Arkowitz retires as CFO on March 15.
- CEO Eric Shaff serves as interim principal financial and accounting officer from March 15 to March 25.
- Thorell receives $480,000 base salary, $80,000 sign-on bonus, and option to purchase 700,000 shares.
- Arkowitz gets 12 months base salary, COBRA coverage, and $500/hour advisory fee for up to 10 hours/month for 6 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524045328/0001193125-24-045328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524045328/d784620d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-045328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer